GlassScriptPhysician profile
Snehal M Bhoola
NPI 1609821016
$9,352.08
in general payments reported to CMS, 2019-2025
69 companies · $886 in 2025
The $886 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,624 · 2020: $140 · 2021: $1,241 · 2022: $2,146 · 2023: $1,668 · 2024: $1,648 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,901 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,901.31 |
| Education | $299.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Momentis Surgical INC. | $1,013.00 | 2022 | |
| Tesaro, INC. | $789.01 | 2019 | |
| Intuitive Surgical, INC. | $724.73 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $562.71 | 2019-2025 | Lynparza, Imfinzi, Enhertu |
| Glaxosmithkline, LLC. | $405.31 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Novartis Pharmaceuticals Corporation | $356.45 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $351.41 | 2019-2024 | Keytruda, Lynparza |
| Eisai INC. | $331.14 | 2020-2025 | |
| Seagen INC. | $324.10 | 2021-2024 | Tukysa |
| Janssen Biotech, INC. | $313.85 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Abbvie INC. | $292.40 | 2019-2025 | |
| Genmab U.S., INC. | $282.99 | 2023-2025 | Tivdak |
| Daiichi Sankyo INC. | $279.72 | 2020-2025 | Enhertu |
| Clovis Oncology, INC. | $250.10 | 2019-2022 | |
| Genzyme Corporation | $209.49 | 2019-2023 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Snehal Bhoola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.